NK cells reject allogeneic and MHC class I-deficient bone marrow (BM) grafts in vivo. The mechanisms used by NK cells to mediate this rejection are not yet thoroughly characterized. Although perforin plays a major role, perforin-independent mechanisms are involved as well. C57BL/6 mice deficient in perforin (B6 perforin knockout (PKO)) reject class I-deficient TAP-1 KO BM cells as efficiently as normal B6 mice. In contrast, perforin-deficient 129S6/SvEvTac mice (129 PKO) cannot mediate this rejection while normal 129 mice efficiently reject. This suggests that in 129, but not in B6, mice, perforin is crucial for NK cell-mediated rejection of MHC class I-deficient BM grafts. To identify loci linked to BM rejection in perforin-deficient mice, we generated backcross 1 progeny by crossing (129 x B6)F(1) PKO mice to 129 PKO mice. In transplantation experiments, >350 backcross 1 progeny were analyzed and displayed a great variation in ability to reject TAP-1 KO BM grafts. PCR-based microsatellite mapping identified four quantitative trait loci (QTL) on chromosomes 2, 4, and 8, with the QTL on chromosome 8 showing the highest significance, as well as a fifth epistatic QTL on chromosome 3. This study describes the first important step toward identifying BM graft resistance gene(s).

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.177.11.7923DOI Listing

Publication Analysis

Top Keywords

class i-deficient
16
mhc class
12
mice
9
quantitative trait
8
trait loci
8
i-deficient bone
8
bone marrow
8
marrow grafts
8
perforin-deficient mice
8
mediate rejection
8

Similar Publications

Article Synopsis
  • Chimeric antigen receptor (CAR) T cells from universal donors can be rejected by the recipient's immune system, which impacts their effectiveness and longevity in treatment.
  • The researchers created HLA class I-deficient T cells to avoid detection by mismatched CD8+ T cells and improved their NK cell tolerance using a specially designed molecule called dtHLA-E4.
  • The optimized dtHLA-E4 molecule showed better surface expression, enhanced NK cell inhibition, and reduced recognition by CD8+ T cells while maintaining the ability to inhibit NK cells, making it a promising strategy for improving the persistence of CAR T cells in treatment.
View Article and Find Full Text PDF

Lymphocyte Activation Gene 3 Expression, γδ T-Cell/Major Histocompatibility Complex Class I Interactions, and Prognosis in Merkel Cell Carcinoma.

Lab Invest

November 2024

Department of Dermatology, Johns Hopkins University, Baltimore, Maryland; Department of Pathology, Johns Hopkins University, Baltimore, Maryland; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland; The Bloomberg∼Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, Maryland; Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland. Electronic address:

Merkel cell carcinoma (MCC) is an aggressive cutaneous malignancy with a poor prognosis. One of the major mechanisms of immune evasion in MCC involves downregulation of major histocompatibility complex class I (MHC-I). Anti-PD-1/programmed death ligand 1 checkpoint inhibitors have revolutionized treatment for MCC, producing objective responses in approximately 50% of patients, and are now the standard of care; however, a substantial proportion of patients either fail to respond or develop resistance to checkpoint inhibitors.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of perioperative chemoimmunotherapy (ChIO) in non-small cell lung cancer (NSCLC), focusing on the role of human leukocyte antigen (HLA) class I expression and loss of heterozygosity (LOH).
  • It involved 24 NSCLC patients, assessing their HLA status and integrating molecular data and clinical outcomes to understand how tumors with HLA class I defects respond to ChIO.
  • Results showed that both HLA-deficient and proficient tumors had similar rates of complete pathological response and survival, with strong immune responses observed in HLA-deficient tumors after treatment.
View Article and Find Full Text PDF

Background: Major histocompatibility complex class I (MHC-I) loss is frequent in non-small cell lung cancer (NSCLC) rendering tumor cells resistant to T cell lysis. NK cells kill MHC-I-deficient tumor cells, and although previous work indicated their presence at NSCLC margins, they were functionally impaired. Within, we evaluated whether NK cell and CD8 T cell infiltration and activation vary with MHC-I expression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!